After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
RMC-5127 becomes the company’s fourth clinical project.
The line-up is revealed to include Merck & Co and J&J itself.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
